See more : ASSA ABLOY AB (publ) (ASSA-B.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Fennec Pharmaceuticals Inc. (FENC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Fennec Pharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Opsens Inc. (OPS.TO) Income Statement Analysis – Financial Results
- Gujarat Fluorochemicals Limited (FLUOROCHEM.BO) Income Statement Analysis – Financial Results
- Seiren Co.,Ltd. (3569.T) Income Statement Analysis – Financial Results
- Danya Cebus Ltd. (DNYA.TA) Income Statement Analysis – Financial Results
- Royal Wins Corporation (SKLL.CN) Income Statement Analysis – Financial Results
Fennec Pharmaceuticals Inc. (FENC)
About Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 21.25M | 1.54M | 0.00 | 170.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.66 | 0.68 |
| Cost of Revenue | 1.26M | 86.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -55.23K | 0.00 |
| Gross Profit | 19.99M | 1.45M | 0.00 | 170.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 55.23K | 0.68 |
| Gross Profit Ratio | 94.08% | 94.40% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 8,359,700.00% | 100.00% |
| Research & Development | 56.00K | 3.53M | 4.98M | 5.11M | 5.61M | 5.01M | 1.94M | 472.00K | 256.00K | 357.00K | 597.00K | 2.08M | 1.49M | 708.00K | 2.11M | 10.37M | 10.91M | 14.00M | 12.44M | 3.59M | 3.55M | 3.13M | 1.91M | 939.36K |
| General & Administrative | 20.59M | 17.72M | 12.24M | 12.95M | 7.40M | 5.40M | 5.02M | 2.40M | 1.63M | 2.52M | 1.33M | 1.55M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 12.12M | 2.79M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 32.71M | 20.51M | 12.24M | 12.95M | 7.40M | 5.40M | 5.02M | 2.40M | 1.63M | 2.52M | 1.33M | 1.55M | 1.94M | 3.90M | 1.21M | 3.52M | 3.28M | 2.88M | 3.18M | 3.49M | 1.78M | 907.40K | 738.72K | 614.25K |
| Other Expenses | 0.00 | 0.00 | 0.00 | -9.00K | -17.00K | 6.00K | -8.00K | -14.00K | 0.00 | 0.00 | -3.00K | -5.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.18M | 2.72M | 2.34M | 1.42M | 0.00 | 55.23K | 52.01K |
| Operating Expenses | 32.76M | 24.04M | 17.22M | 18.06M | 13.01M | 10.41M | 6.95M | 2.87M | 1.89M | 2.88M | 1.93M | 3.62M | 3.44M | 4.60M | 2.83M | 13.89M | 14.19M | 19.06M | 18.35M | 9.42M | 6.74M | 4.04M | 2.70M | 1.61M |
| Cost & Expenses | 34.06M | 24.12M | 17.22M | 18.06M | 13.01M | 10.41M | 6.95M | 2.87M | 1.89M | 2.88M | 1.93M | 3.62M | 3.44M | 4.60M | 2.83M | 13.89M | 14.19M | 19.06M | 18.35M | 9.42M | 6.74M | 4.04M | 2.65M | 1.61M |
| Interest Income | 441.00K | 195.00K | 54.00K | 87.00K | 322.32K | 0.00 | 0.00 | 0.00 | 3.00K | 2.00K | 2.00K | 25.00K | 43.00K | 32.00K | 47.00K | 286.00K | 833.00K | 0.00 | 361.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 3.39M | 978.00K | 126.00K | 9.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.00K | 11.00K | -444.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 287.00K | 149.00K | 17.22M | 402.00K | 13.01M | 10.41M | 6.95M | 2.87M | -1.23M | -699.00K | -1.00K | 20.00K | 43.00K | 3.25M | 615.00K | 164.00K | 192.00K | 2.43M | 3.06M | 2.52M | 1.61M | 123.76K | 55.23K | 52.01K |
| EBITDA | -12.36M | -22.59M | -123.00K | -17.89M | 234.00K | 521.00K | -95.00K | 82.00K | -1.89M | -2.88M | 1.79M | -5.18M | 4.55M | -4.60M | -2.60M | -13.89M | -14.19M | -17.91M | -19.27M | -12.56M | -5.22M | -4.24M | -2.79M | -2.59M |
| EBITDA Ratio | -58.18% | -1,468.60% | 0.00% | -10,579.41% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -421,928,118.14% | -231,162,432.56% |
| Operating Income | -12.77M | -22.59M | -17.22M | -17.89M | -13.01M | -10.41M | -6.95M | -2.87M | -1.89M | -2.88M | -1.93M | -3.62M | -3.44M | -4.60M | -3.22M | -13.89M | -14.19M | -19.06M | -18.35M | -9.42M | -6.74M | -4.04M | -2.65M | -1.61M |
| Operating Income Ratio | -60.09% | -1,471.60% | 0.00% | -10,520.59% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -400,900,112.25% | -237,629,943.17% |
| Total Other Income/Expenses | -3.27M | -1.13M | -123.00K | -224.00K | 234.00K | 521.00K | -95.00K | 82.00K | 1.28M | 701.00K | 3.78M | -1.54M | 8.12M | -3.51M | 204.00K | 0.00 | 905.96K | -1.54M | -3.99M | -227.00K | 79.44K | 321.36K | 194.17K | 8.31K |
| Income Before Tax | -16.05M | -23.71M | -17.35M | -18.11M | -12.78M | -9.89M | -7.05M | -2.79M | -659.00K | -2.18M | 1.85M | -5.16M | 4.69M | -7.82M | -3.01M | -13.60M | -13.36M | -20.64M | -21.54M | -9.59M | -6.67M | -3.72M | -2.45M | -1.60M |
| Income Before Tax Ratio | -75.50% | -1,544.89% | 0.00% | -10,652.35% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -371,512,604.02% | -236,400,367.04% |
| Income Tax Expense | 0.00 | 1.13M | 110.00K | -187.00K | -315.00K | -348.00K | -47.00K | -8.00K | -3.00K | -2.00K | -2.00K | -25.00K | -43.00K | 7.82M | 3.01M | 13.60M | 13.36M | -1.54M | -2.29M | -854.68K | -518.20K | 3.72M | 2.45M | 1.60M |
| Net Income | -16.05M | -24.84M | -17.46M | -17.92M | -12.46M | -9.89M | -7.05M | -2.79M | -659.00K | -2.18M | 1.85M | -5.16M | 4.69M | -7.82M | -3.01M | -13.60M | -13.36M | -19.10M | -19.25M | -8.74M | -6.15M | -3.72M | -2.45M | -1.60M |
| Net Income Ratio | -75.50% | -1,618.18% | 0.00% | -10,542.35% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -371,512,604.02% | -236,400,367.04% |
| EPS | -0.60 | -0.95 | -0.67 | -0.76 | -0.63 | -0.52 | -0.47 | -0.22 | -0.06 | -0.22 | 0.19 | -0.63 | 0.59 | -1.11 | -0.98 | -4.43 | -4.78 | -16.72 | -20.45 | -15.04 | -19.85 | -19.32 | -20.12 | -2.98 |
| EPS Diluted | -0.60 | -0.95 | -0.67 | -0.76 | -0.63 | -0.52 | -0.47 | -0.22 | -0.06 | -0.22 | 0.17 | -0.62 | 0.58 | -1.11 | -0.98 | -4.43 | -4.78 | -16.72 | -20.45 | -15.04 | -19.85 | -19.32 | -4.04 | -2.98 |
| Weighted Avg Shares Out | 26.57M | 26.28M | 26.01M | 23.70M | 19.90M | 18.94M | 14.99M | 12.68M | 10.83M | 9.87M | 9.72M | 8.20M | 7.99M | 7.08M | 3.07M | 3.07M | 2.79M | 1.14M | 941.26K | 580.75K | 309.64K | 192.51K | 122.02K | 536.64K |
| Weighted Avg Shares Out (Dil) | 26.57M | 26.28M | 26.01M | 23.70M | 19.90M | 19.02M | 15.01M | 12.77M | 10.83M | 9.87M | 10.57M | 8.39M | 8.02M | 7.08M | 3.07M | 3.07M | 2.79M | 1.14M | 941.26K | 580.75K | 309.64K | 192.51K | 607.09K | 536.64K |
Fennec Pharmaceuticals Announces Amendment to Increase Existing Senior Debt Facility
RESEARCH TRIANGLE PARK, N.C., June 24, 2021 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric...
Fennec Pharma Stock Is Trading Higher As Pedmark Is Under FDA Review For Chemo-Induced Toxicity
The FDA has accepted for review Fennec Pharmaceuticals Inc's (NASDAQ: FENC) resubmitted marketing application seeking approval for Pedmark (formulated sodium thiosulfate) to prevent ototoxicity induced by cisplatin chemotherapy. The application covers patients one month to < 18 years of age with localized, non-metastatic,...
Fennec Pharmaceuticals Announces FDA Acceptance of New Drug Application Resubmission for PEDMARK™
~ Prescription Drug User Fee Act (PDUFA) Target Action Date Set for November 27, 2021 ~
Fennec Pharma Refiles Pedmark US Application For Cisplatin-Induced Ototoxicity In Pediatric Patients
Fennec Pharmaceuticals Inc (NASDAQ: FENC) has resubmitted its marketing application to the FDA seeking approval for Pedmark (formulated sodium thiosulfate) for the prevention of ototoxicity (toxic to the ear) induced by cisplatin chemotherapy in patients one month, to less than 18 years, with...
5 Pre-Market Stock Gainers For May 28: VTNR, ITRM, MTEX, AMC, FENC
Here is an overview of 5 of the top stock gainers for May 28 during pre-market and why the stock prices moved. The post 5 Pre-Market Stock Gainers For May 28: VTNR, ITRM, MTEX, AMC, FENC appeared first on Pulse...
Fennec Pharmaceuticals Resubmits New Drug Application to U.S. Food and Drug Administration for PEDMARK™
~ If Approved by the FDA, PEDMARK Stands to Be the First Therapy for the Prevention of Cisplatin-Induced Hearing Loss in Children ~ ~ If Approved by the FDA, PEDMARK Stands to Be the First Therapy for the Prevention of...
Fennec Pharmaceuticals Announces First Quarter 2021 Financial Results and Provides Business Update
~ Fennec Remains on Track to Finalize and Resubmit the New Drug Application for PEDMARK™ to the U.S. Food and Drug Administration in the Second Quarter of 2021 ~
ScPharmaceuticals: The Third Time's A Charm
ScPharmaceuticals: The Third Time's A Charm
Fennec Announces Fiscal Year 2020 Financial Results and Provides Business Update
~ Fennec is Working Closely with its Third-Party Drug Product Manufacturer to Finalize the New Drug Application (NDA) Resubmission for PEDMARK™ ~
Fennec Pharmaceuticals Announces Third Quarter 2020 Financial Results and Provides Business Update
~ The Company Continues to Work with the FDA and Its Third-Party Drug Product Manufacturer to Fully Address CRL and Prepare NDA Resubmission for PEDMARK™ ~
Source: https://incomestatements.info
Category: Stock Reports